Search Results

Welcome to CREATE Health Our vision: To contribute with innovative diagnostics and therapeutic solutions not for coming generations but for today's CREATE Health aims to provide individualized and improved therapeutic strategies, based on…

https://www.createhealth.lth.se/start- 2025-06-05

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna…

https://www.createhealth.lth.se/about/centre-management-and-board- 2025-06-05

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment- 2025-06-03

 Please wait...

https://www.createhealth.lth.se/about/principle-investigators- 2025-06-03

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s…

https://www.createhealth.lth.se/research-and-innovation/ongoing-collaborations-and-partners- 2025-06-03

CantargiaCantargia AB was founded in 2009/2010 by Thoas Fioretos and Marcus Järås (Lund University), Kjell Sjöström (Innovagen), and by LU Bioscience. The company specializes in antibody-based cancer therapy. After initially focusing on…

https://www.createhealth.lth.se/research-and-innovation/spin-outs- 2025-06-03

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility…

https://www.createhealth.lth.se/canfaster- 2025-06-04

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh…

https://www.createhealth.lth.se/canfaster/publications- 2025-06-10

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1sNext generation immuno-oncological targets for cancer therapySubtype-dependent biomarkers for systemic therapy in bladder cancer

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects- 2025-06-05

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s- 2025-06-10

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy- 2025-06-10

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer- 2025-06-10

Address Medicon Village - Building 406Sheelevägen 2 223 81 LundSweden Are you applying for a position? For general questions regarding the call, contact us at:canfaster-postdoc [at] immun [dot] lth [dot] se (canfaster-postdoc[at]immun[dot…

https://www.createhealth.lth.se/canfaster/contact- 2025-06-05

 Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden

https://www.createhealth.lth.se/contact- 2025-06-04

Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solutions, which can be implemented into the clinic with much shorter lead…

https://www.createhealth.lth.se/about- 2025-05-15

Focus AreasPsychological Resilience in Cancer, Bioinformatics and AIOngoing Collaborations and partnersCantargia, IMMUNOVIA, Paindrainer, Akuru PharmaSpin OutsWorking together is an integral part of CREATE Health’s DNA 

https://www.createhealth.lth.se/research-and-innovation- 2025-06-05

CREATE Health has been a leader in developing novel therapeutic and diagnostic innovations, which have been further developed in a commercial setting in a start-up company. Immuno-OncologyImmuno-oncology has provided a number of very…

https://www.createhealth.lth.se/research-and-innovation/focus-areas- 2025-06-05

In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are…

https://www.createhealth.lth.se/about/funding- 2025-06-03